{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Error analysis for the type of examples that Punctuation and Digit get wrong compared to the baseline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "%autoreload\n",
    "import os\n",
    "from sys import path\n",
    "import re\n",
    "import pandas as pd\n",
    "path.append('../..')\n",
    "import numpy as np\n",
    "from scipy.stats import ttest_rel\n",
    "from relation_extraction.data.summarize import *\n",
    "from relation_extraction.data.converters.converter_ddi import relation_dict\n",
    "output_path = '/scratch/geeticka/relation-extraction-result/ddi-analyze/'\n",
    "def res(path): return os.path.join(output_path, path)\n",
    "original_sentences_path = os.path.join('/scratch/geeticka/relation-extraction-result/ddi-analyze/test_original.txt')\n",
    "punct_digit_sentences_path = os.path.join('/crimea/geeticka/data/relation_extraction/ddi/pre-processed/punct_digit/test_punct_digit.txt')\n",
    "relation_full_form_dictionary = {'advise': 'Advise', 'effect': 'Effect', 'mechanism': 'Mechanism',\n",
    "                                 'int': 'Interaction', 'none': 'None'}\n",
    "relation_as_short_list = ['advise', 'effect', 'mechanism', 'int', 'none']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{0: 'advise', 1: 'effect', 2: 'mechanism', 3: 'int', 4: 'none'}"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relation_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "# confusion_matrix_portion = '<<< 8-WAY EVALUATION >>>'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "# summary_cm_baseline, summary_cm_conceptblind = print_full_summary('i2b2',\n",
    "#     'result-baseline-i2b2.txt', 'result-concblind-i2b2.txt', \n",
    "#     'Baseline','Concept-Blind', res, relation_full_form_dictionary, relation_as_short_list, confusion_matrix_portion, 2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "# summary_cm_baseline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "# summary_cm_conceptblind"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_answers_line(line):\n",
    "    linenum, relation = line.strip().split()\n",
    "    return linenum, relation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "def asstring(list_of_strings):\n",
    "    return \" \".join(list_of_strings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_sentence_and_entities(line):\n",
    "    line = line.strip().split()\n",
    "    sentence = line[5:]\n",
    "    relation = relation_dict[int(line[0])]\n",
    "    entity1_idx = (int(line[1]), int(line[2]))\n",
    "    entity2_idx = (int(line[3]), int(line[4]))\n",
    "    entity1 = sentence[entity1_idx[0] : entity1_idx[1] + 1]\n",
    "    entity2 = sentence[entity2_idx[0] : entity2_idx[1] + 1]\n",
    "    \n",
    "    return relation, asstring(entity1), asstring(entity2), asstring(sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "needed_linenum_and_relation = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(res(\"answers_for_dev-punct-digit.txt\")) as textfile1, open(res('answers_for_dev-baseline.txt')) as textfile2, \\\n",
    "open(res('answers_for_dev-baseline_gold.txt')) as textfile3: \n",
    "    for x, y, z in zip(textfile1, textfile2, textfile3):\n",
    "        linenum, punct_digit_relation = read_answers_line(x)\n",
    "        _, baseline_relation = read_answers_line(y)\n",
    "        _, gold_relation = read_answers_line(z)\n",
    "        if baseline_relation == gold_relation and punct_digit_relation != gold_relation: # punct digit making mistakes\n",
    "            needed_linenum_and_relation[int(linenum) - 1] = (baseline_relation, punct_digit_relation)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "150"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(needed_linenum_and_relation.keys()))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Remember that baseline is correct here so the first relation listed is the correct one, unlike in the i2b2 notebook where the order is reversed because baseline is the incorrect one there"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We print the baseline first and then the punct digit version. Gold relation corresponds to baseline\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Terbinafine, rifampin \n",
      "Sentences: \n",
      "\tTerbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . \n",
      "\t Terbinafine clearance is increased NUMBER by rifampin a CyP450 enzyme inducer and decreased NUMBER by cimetidine a CyP450 enzyme inhibitor\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Terbinafine, cimetidine \n",
      "Sentences: \n",
      "\tTerbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . \n",
      "\t Terbinafine clearance is increased NUMBER by rifampin a CyP450 enzyme inducer and decreased NUMBER by cimetidine a CyP450 enzyme inhibitor\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t gemfibrozil, rosiglitazone \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An inhibitor of CYP2C8 such as gemfibrozil may increase the AUC of rosiglitazone and an inducer of CYP2C8 such as rifampin may decrease the AUC of rosiglitazone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t rifampin, rosiglitazone \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An inhibitor of CYP2C8 such as gemfibrozil may increase the AUC of rosiglitazone and an inducer of CYP2C8 such as rifampin may decrease the AUC of rosiglitazone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Trimethoprim, phenytoin \n",
      "Sentences: \n",
      "\tTrimethoprim , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . \n",
      "\t Trimethoprim given at a common clinical dosage increased the phenytoin half life by NUMBER and decreased the phenytoin metabolic clearance rate by NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenytoin, phenytoin \n",
      "Sentences: \n",
      "\tTrimethoprim , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . \n",
      "\t Trimethoprim given at a common clinical dosage increased the phenytoin half life by NUMBER and decreased the phenytoin metabolic clearance rate by NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t mexiletine, propafenone \n",
      "Sentences: \n",
      "\tAddition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . \n",
      "\t Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS QTc RR and PR intervals than propafenone alone\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Mexitil, diuretics \n",
      "Sentences: \n",
      "\tECG intervals ( PR , QRS , and QT ) were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . \n",
      "\t ECG intervals PR QRS and QT were not affected by concurrent Mexitil and digoxin diuretics or propranolol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Mexitil, propranolol \n",
      "Sentences: \n",
      "\tECG intervals ( PR , QRS , and QT ) were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . \n",
      "\t ECG intervals PR QRS and QT were not affected by concurrent Mexitil and digoxin diuretics or propranolol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Mexitil, digoxin \n",
      "Sentences: \n",
      "\tMexitil does not alter serum digoxin levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . \n",
      "\t Mexitil does not alter serum digoxin levels but magnesium aluminum hydroxide when used to treat gastrointestinal symptoms due to Mexitil has been reported to lower serum digoxin levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Mexitil, theophylline \n",
      "Sentences: \n",
      "\tConcurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . \n",
      "\t Concurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Mexitil, theophylline \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This increase was observed at the first test point which was the second day after starting Mexitil Theophylline plasma levels returned to pre- Mexitil values within NUMBER hours after discontinuing Mexitil If Mexitil and theophylline are to be used concurrently theophylline blood levels should be monitored particularly when the Mexitil dose is changed\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t halothane, DIPRIVAN \n",
      "Sentences: \n",
      "\tThe concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . \n",
      "\t The concurrent administration of potent inhalational agents eg isoflurane enflurane and halothane during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Posicor, tricyclic antidepressants \n",
      "Sentences: \n",
      "\tPosicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . \n",
      "\t Posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine astemizole cisapride cyclosporine and tricyclic antidepressants\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t CNS depressants, alcohol \n",
      "Sentences: \n",
      "\tPhenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . ) \n",
      "\t Phenothiazines are capable of potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t barbiturates, anesthetics \n",
      "Sentences: \n",
      "\tPhenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . ) \n",
      "\t Phenothiazines are capable of potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t barbiturates, opiates \n",
      "Sentences: \n",
      "\tPhenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . ) \n",
      "\t Phenothiazines are capable of potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t barbiturates, alcohol \n",
      "Sentences: \n",
      "\tPhenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . ) \n",
      "\t Phenothiazines are capable of potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t SKELID, aluminum \n",
      "Sentences: \n",
      "\tThe bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . \n",
      "\t The bioavailability of SKELID is decreased NUMBER by calcium when calcium and SKELID are administered at the same time and NUMBER by some aluminum or magnesium -containing antacids when administered NUMBER hour before SKELID\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t SKELID, SKELID \n",
      "Sentences: \n",
      "\tThe bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . \n",
      "\t The bioavailability of SKELID is decreased NUMBER by calcium when calcium and SKELID are administered at the same time and NUMBER by some aluminum or magnesium -containing antacids when administered NUMBER hour before SKELID\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t antacids, SKELID \n",
      "Sentences: \n",
      "\tThe bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium -containing antacids , when administered 1 hour before SKELID . \n",
      "\t The bioavailability of SKELID is decreased NUMBER by calcium when calcium and SKELID are administered at the same time and NUMBER by some aluminum or magnesium -containing antacids when administered NUMBER hour before SKELID\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, digoxin \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t Drugs Eliminated by Active Tubular Secretion Although studies to assess drug drug interactions with Sanctura have not been conducted Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin and tenofovir\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, tenofovir \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t Drugs Eliminated by Active Tubular Secretion Although studies to assess drug drug interactions with Sanctura have not been conducted Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin and tenofovir\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t MIVACRON, succinylcholine \n",
      "Sentences: \n",
      "\tAlthough MIVACRON ( a mixture of three stereoisomers ) has been administered safely following succinylcholine - facilitated tracheal intubation , the interaction between MIVACRON and succinylcholine has not been systematically studied . \n",
      "\t Although MIVACRON a mixture of NUMBER stereoisomers has been administered safely following succinylcholine facilitated tracheal intubation the interaction between MIVACRON and succinylcholine has not been systematically studied\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptase, antiplatelet agents \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of Anticoagulants and Antiplatelet Agents Streptase Streptokinase alone or in combination with antiplatelet agents and anticoagulants may cause bleeding complications\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptase, anticoagulants \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of Anticoagulants and Antiplatelet Agents Streptase Streptokinase alone or in combination with antiplatelet agents and anticoagulants may cause bleeding complications\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptokinase, antiplatelet agents \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of Anticoagulants and Antiplatelet Agents Streptase Streptokinase alone or in combination with antiplatelet agents and anticoagulants may cause bleeding complications\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Nalidixic acid, melphalan \n",
      "Sentences: \n",
      "\tDRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . \n",
      "\t DRUG INTERACTIONS There are no known drug drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t cimetidine, mebendazole \n",
      "Sentences: \n",
      "\tPreliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . \n",
      "\t Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Pindolol, thioridazine \n",
      "Sentences: \n",
      "\tPindolol has been shown to increase serum thioridazine levels when both drugs are co - administered . \n",
      "\t Pindolol has been shown to increase serum thioridazine levels when both drugs are co administered\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Ropivacaine, ropivacaine \n",
      "Sentences: \n",
      "\tThus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . \n",
      "\t Thus strong inhibitors of cytochrome P4501A2 such as fluvoxamine given concomitantly during administration of Ropivacaine can interact with Ropivacaine leading to increased ropivacaine plasma levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketoconazole, ropivacaine \n",
      "Sentences: \n",
      "\tCoadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in - vivo plasma clearance of ropivacaine . \n",
      "\t Coadministration of a selective and potent inhibitor of CYP3A4 ketoconazole NUMBER mg bid for NUMBER days with ropivacaine infusion administered NUMBER hour after ketoconazole caused a NUMBER reduction in in vivo plasma clearance of ropivacaine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ZAVESCA, Cerezyme \n",
      "Sentences: \n",
      "\tWhile co - administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . \n",
      "\t While co administration of ZAVESCA appeared to increase the clearance of Cerezyme by NUMBER these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Cerezyme, imiglucerase \n",
      "Sentences: \n",
      "\tCombination therapy with Cerezyme ( imiglucerase ) and ZAVESCA is not indicated . \n",
      "\t Combination therapy with Cerezyme imiglucerase and ZAVESCA is not indicated\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ZEMURON, succinylcholine \n",
      "Sentences: \n",
      "\tThe median duration of action of ZEMURON 0.6 mg / kg administered after a 1 mg / kg dose of succinylcholine when T 1 returned to 75 % of control was 36 minutes ( range 14 - 57 , n=12 ) vs. \n",
      "\t The median duration of action of ZEMURON NUMBER mg kg administered after a NUMBER mg kg dose of succinylcholine when T NUMBER returned to NUMBER of control was NUMBER minutes range NUMBER NUMBER n=12 vs.\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t alcohol, methyprylon \n",
      "Sentences: \n",
      "\tConcurrent use of alcohol and other CNS depression - producing drugs may increase the CNS depressant effects of methyprylon or these other medications . \n",
      "\t Concurrent use of alcohol and other CNS depression producing drugs may increase the CNS depressant effects of methyprylon or these other medications\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t FELDENE, aspirin \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t Plasma levels of piroxicam are depressed to approximately NUMBER of their normal values when FELDENE is administered in conjunction with aspirin NUMBER mg day but concomitant administration of antacids has no effect on piroxicam plasma levels Nonsteroidal anti inflammatory agents including FELDENE have been reported to increase steady state plasma lithium levels\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t aspirin, meloxicam \n",
      "Sentences: \n",
      "\tAspirin : Concomitant administration of aspirin ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of meloxicam . \n",
      "\t Aspirin Concomitant administration of aspirin NUMBER mg TID to healthy volunteers tended to increase the AUC NUMBER and Cmax NUMBER of meloxicam\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t digoxin, meloxicam \n",
      "Sentences: \n",
      "\tIn vitro testing found no protein binding drug interaction between digoxin and meloxicam . \n",
      "\t In vitro testing found no protein binding drug interaction between digoxin and meloxicam\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t furosemide, thiazide diuretics \n",
      "Sentences: \n",
      "\tFurosemide : Clinical studies , as well as post - marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . \n",
      "\t Furosemide Clinical studies as well as post marketing observations have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t meloxicam, warfarin \n",
      "Sentences: \n",
      "\tThe effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . \n",
      "\t The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR International Normalized Ratio between NUMBER and NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t warfarin, warfarin \n",
      "Sentences: \n",
      "\tThe effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . \n",
      "\t The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR International Normalized Ratio between NUMBER and NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t lamivudine, zidovudine \n",
      "Sentences: \n",
      "\tPharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . \n",
      "\t Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t paricalcitol, ketoconazole \n",
      "Sentences: \n",
      "\tA multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . \n",
      "\t A multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin or voriconazole\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t riboflavin, probenecid \n",
      "Sentences: \n",
      "\trequirements for riboflavin may be increased in patients receiving probenecid . \n",
      "\t requirements for riboflavin may be increased in patients receiving probenecid\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ezetimibe, statins \n",
      "Sentences: \n",
      "\tMultiple dose studies of ezetimibe given in combination with HMG - CoA reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . \n",
      "\t Multiple dose studies of ezetimibe given in combination with HMG CoA reductase inhibitors statins in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Methscopolamine, phenothiazines \n",
      "Sentences: \n",
      "\tMethscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . \n",
      "\t Methscopolamine may interact with antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine other anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Vindesine, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Live virus vaccines, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Live virus vaccines, Mitomycin - C \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Mitomycin - C, Killed virus vaccines \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Mitomycin - C, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Killed virus vaccines, vaccine \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t Vindesine can interact with the drugs of the following categories Blood dyscrasia can cause unpredictable myelotoxicity Bone marrow depressants can cause a predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications can cause neurologic toxicity Phenytoin can increase seizure activity Live virus vaccines may potentiate the replication of the vaccine virus may increase the side effects of the vaccination and decrease patient 's response to the vaccine Mitomycin C may cause shortness of breath and bronchospasm Killed virus vaccines may decrease patient 's response to the vaccine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t anticonvulsants, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort and certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels of mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort and certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels of mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenobarbital, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort and certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels of mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t carbamazepine, mifepristone \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort and certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels of mifepristone\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t methylergonovine maleate, ergot alkaloids \n",
      "Sentences: \n",
      "\tCaution should be exercised when Methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids . \n",
      "\t Caution should be exercised when Methergine methylergonovine maleate is used concurrently with other vasoconstrictors or ergot alkaloids\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t thiabendazole, xanthine derivatives \n",
      "Sentences: \n",
      "\tTherefore , when concomitant use of thiabendazole and xanthine derivatives is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds . \n",
      "\t Therefore when concomitant use of thiabendazole and xanthine derivatives is anticipated it may be necessary to monitor blood levels and/or reduce the dosage of such compounds\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t alcohol, mirtazapine \n",
      "Sentences: \n",
      "\tAlcohol : Concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects . \n",
      "\t Alcohol Concomitant administration of alcohol equivalent to NUMBER g had a minimal effect on plasma levels of mirtazapine NUMBER mg in NUMBER healthy male subjects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t alcohol, Diazepam \n",
      "Sentences: \n",
      "\tAccordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . \n",
      "\t Accordingly patients should be advised to avoid alcohol while taking REMERON SolTab Diazepam Concomitant administration of diazepam NUMBER mg had a minimal effect on plasma levels of mirtazapine NUMBER mg in NUMBER healthy subjects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t alcohol, diazepam \n",
      "Sentences: \n",
      "\tAccordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . \n",
      "\t Accordingly patients should be advised to avoid alcohol while taking REMERON SolTab Diazepam Concomitant administration of diazepam NUMBER mg had a minimal effect on plasma levels of mirtazapine NUMBER mg in NUMBER healthy subjects\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t corticosteroids, corticosteroid \n",
      "Sentences: \n",
      "\tDrugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . \n",
      "\t Drugs that induce hepatic enzymes such as phenobarbital phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Gentamicin, perindopril \n",
      "Sentences: \n",
      "\tGentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . \n",
      "\t Gentamicin Animal data have suggested the possibility of interaction between perindopril and gentamicin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Gentamicin, gentamicin \n",
      "Sentences: \n",
      "\tGentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . \n",
      "\t Gentamicin Animal data have suggested the possibility of interaction between perindopril and gentamicin\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t ACEON, perindopril \n",
      "Sentences: \n",
      "\tFood Interaction : Oral administration of ACEON Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state . \n",
      "\t Food Interaction Oral administration of ACEON Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t pentazocine, opioid agonist analgesic \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t Interaction with Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol or buprenorphine should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t MYCAMINE, mycophenolate mofetil \n",
      "Sentences: \n",
      "\tA total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . \n",
      "\t A total of NUMBER clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir and rifampin\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t anticholinergic drugs, triprolidine \n",
      "Sentences: \n",
      "\tThe effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . \n",
      "\t The effects of anticholinergic drugs such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t MAO inhibitors, pseudoephedrine \n",
      "Sentences: \n",
      "\tMAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . \n",
      "\t MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t TOBI, aminoglycosides \n",
      "Sentences: \n",
      "\tIn clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta)-agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . \n",
      "\t In clinical studies of TOBI patients taking TOBI concomitantly with dornase alfa PULMOZYME Genentech beta)-agonists inhaled corticosteroids other anti pseudomonal antibiotics or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t vasoconstrictor agents, sumatriptan \n",
      "Sentences: \n",
      "\tConcurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . \n",
      "\t Concurrent use with vasoconstrictor agents including ergot alkaloids sumatriptan and nicotine e.g. smoking may result in enhanced vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t vasoconstrictor agents, nicotine \n",
      "Sentences: \n",
      "\tConcurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . \n",
      "\t Concurrent use with vasoconstrictor agents including ergot alkaloids sumatriptan and nicotine e.g. smoking may result in enhanced vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sumatriptan, nicotine \n",
      "Sentences: \n",
      "\tConcurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . \n",
      "\t Concurrent use with vasoconstrictor agents including ergot alkaloids sumatriptan and nicotine e.g. smoking may result in enhanced vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t calcium channel antagonists, macrolide antibiotics \n",
      "Sentences: \n",
      "\tDrug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) . \n",
      "\t Drug Interactions Inhibitors of CYP3A4 Isozymes Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ie some drugs in the drug classes of azole antimycotics protease inhibitors calcium channel antagonists and macrolide antibiotics\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t erythromycin, verapamil \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t Drugs such as erythromycin diltiazem verapamil ketoconazole fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t fluconazole, midazolam \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t Drugs such as erythromycin diltiazem verapamil ketoconazole fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t itraconazole, midazolam \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t Drugs such as erythromycin diltiazem verapamil ketoconazole fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t carbamazepine, phenytoin \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers of CYP3A4 Isozymes Cytochrome P450 inducers such as rifampin carbamazepine and phenytoin induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, midazolam \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t Inducers of CYP3A4 Isozymes Cytochrome P450 inducers such as rifampin carbamazepine and phenytoin induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, droperidol \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system particularly narcotics eg morphine meperidine and fentanyl propofol ketamine nitrous oxide secobarbital and droperidol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinomimetics, Cholinesterase Inhibitors \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine similar neuromuscular blocking agents or cholinergic agonists such as bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinomimetics, cholinesterase inhibitors \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine similar neuromuscular blocking agents or cholinergic agonists such as bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Cholinomimetics, cholinergic agonists \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine similar neuromuscular blocking agents or cholinergic agonists such as bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t cholinesterase inhibitors, succinylcholine \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine similar neuromuscular blocking agents or cholinergic agonists such as bethanechol\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t TRENTAL, theophylline \n",
      "Sentences: \n",
      "\tConcomitant administration of TRENTAL and theophylline -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . \n",
      "\t Concomitant administration of TRENTAL and theophylline -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Cholestyramine, mycophenolate mofetil \n",
      "Sentences: \n",
      "\tCholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil . \n",
      "\t Cholestyramine and Drugs that Bind Bile Acids These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Live Vaccines, Myfortic \n",
      "Sentences: \n",
      "\tLive Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . \n",
      "\t Live Vaccines During treatment with Myfortic the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenytoin, phenobarbital \n",
      "Sentences: \n",
      "\tSince Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . \n",
      "\t Since Celontin methsuximide may interact with concurrently administered antiepileptic drugs periodic serum level determinations of these drugs may be necessary eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t vancomycin, anesthetic agents \n",
      "Sentences: \n",
      "\tConcomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine - like flushing and anaphylactoid reactions . \n",
      "\t Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine like flushing and anaphylactoid reactions\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Melatonin, NSAIDs \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin may interact with the following drugs aspirin and other NSAIDs may lower melatonin levels fluvoxamine bioavailability of oral melatonin is increased with coadministration beta blockers may decrease melatonin levels fluoxetine reports of psychotic episodes when coadministered progestin coadministration of melatonin with progestin can inhibit ovarian function in women benzodiazepenes and other sedating drugs may result in additive sedation and an increased incidence of adverse effects and corticosteroids coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t melatonin, benzodiazepenes \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin may interact with the following drugs aspirin and other NSAIDs may lower melatonin levels fluvoxamine bioavailability of oral melatonin is increased with coadministration beta blockers may decrease melatonin levels fluoxetine reports of psychotic episodes when coadministered progestin coadministration of melatonin with progestin can inhibit ovarian function in women benzodiazepenes and other sedating drugs may result in additive sedation and an increased incidence of adverse effects and corticosteroids coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melatonin, corticosteroids \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin may interact with the following drugs aspirin and other NSAIDs may lower melatonin levels fluvoxamine bioavailability of oral melatonin is increased with coadministration beta blockers may decrease melatonin levels fluoxetine reports of psychotic episodes when coadministered progestin coadministration of melatonin with progestin can inhibit ovarian function in women benzodiazepenes and other sedating drugs may result in additive sedation and an increased incidence of adverse effects and corticosteroids coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t melatonin, corticosteroids \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t Melatonin may interact with the following drugs aspirin and other NSAIDs may lower melatonin levels fluvoxamine bioavailability of oral melatonin is increased with coadministration beta blockers may decrease melatonin levels fluoxetine reports of psychotic episodes when coadministered progestin coadministration of melatonin with progestin can inhibit ovarian function in women benzodiazepenes and other sedating drugs may result in additive sedation and an increased incidence of adverse effects and corticosteroids coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Caffeine, levomepromazine \n",
      "Sentences: \n",
      "\tCaffeine and/or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of levomepromazine . \n",
      "\t Caffeine and/or stimulantes of the ephedrine amphetamine type may counteract the specific actions of levomepromazine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, montelukast \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t Phenobarbital which induces hepatic metabolism decreased the AUC of montelukast approximately NUMBER following a single 10-mg dose of montelukast\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, montelukast \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t Phenobarbital which induces hepatic metabolism decreased the AUC of montelukast approximately NUMBER following a single 10-mg dose of montelukast\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t pseudoephedrine, ProAmatine \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The use of drugs that stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine or dihydroergotamine may enhance or potentiate the pressor effects of ProAmatine Therefore caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t ephedrine, ProAmatine \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The use of drugs that stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine or dihydroergotamine may enhance or potentiate the pressor effects of ProAmatine Therefore caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t phenylpropanolamine, ProAmatine \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The use of drugs that stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine or dihydroergotamine may enhance or potentiate the pressor effects of ProAmatine Therefore caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t barbiturates, reserpine \n",
      "Sentences: \n",
      "\tThalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . \n",
      "\t Thalidomide has been reported to enhance the sedative activity of barbiturates alcohol chlorpromazine and reserpine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t chlorpromazine, reserpine \n",
      "Sentences: \n",
      "\tThalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . \n",
      "\t Thalidomide has been reported to enhance the sedative activity of barbiturates alcohol chlorpromazine and reserpine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Thalidomide, Hormonal Contraceptives \n",
      "Sentences: \n",
      "\tImportant Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. \n",
      "\t Important Non- Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives Concomitant use of HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine or certain herbal supplements such as St.\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t fluconazole, terfenadine \n",
      "Sentences: \n",
      "\tDue to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . \n",
      "\t Due to the chemical similarity of other azole type antifungal agents including fluconazole metronidazole and miconazole to ketoconazole and itraconazole concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t terfenadine, macrolide antibiotics \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t terfenadine, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t clarithromycin, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t erythromycin, macrolide antibiotics \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t erythromycin, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t troleandomycin, terfenadine \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t troleandomycin, macrolide antibiotics \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t troleandomycin, azithromycin \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t Concomitant administration of terfenadine with clarithromycin erythromycin or troleandomycin is contraindicated Pending full characterization of potential interactions concomitant administration of terfenadine with other macrolide antibiotics including azithromycin is not recommended\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t UNIVASC, hydrochlorothiazide \n",
      "Sentences: \n",
      "\tOther Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . \n",
      "\t Other Agents No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide digoxin or cimetidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t UNIVASC, digoxin \n",
      "Sentences: \n",
      "\tOther Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . \n",
      "\t Other Agents No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide digoxin or cimetidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t UNIVASC, cimetidine \n",
      "Sentences: \n",
      "\tOther Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . \n",
      "\t Other Agents No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide digoxin or cimetidine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t antimycotic agents, oxybutynin \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t Other inhibitors of the cytochrome P450 3A4 enzyme system such as antimycotic agents e.g. itraconazole and miconazole or macrolide antibiotics e.g. erythromycin and clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax and AUC\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t atropine, pralidoxime \n",
      "Sentences: \n",
      "\tThis is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed . \n",
      "\t This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t cimetidine, pramipexole \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other drugs eliminated via renal secretion Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine and quinine decreases the oral clearance of pramipexole by about NUMBER while those secreted by the anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide and chlorpropamide are likely to have little effect on the oral clearance of pramipexole\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t ranitidine, pramipexole \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other drugs eliminated via renal secretion Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine and quinine decreases the oral clearance of pramipexole by about NUMBER while those secreted by the anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide and chlorpropamide are likely to have little effect on the oral clearance of pramipexole\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t vitamin K antagonists, TNKase \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t Anticoagulants such as heparin and vitamin K antagonists and drugs that alter platelet function such as acetylsalicylic acid dipyridamole and GP IIb IIIa inhibitors may increase the risk of bleeding if administered prior to during or after TNKase therapy\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dipyridamole, TNKase \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t Anticoagulants such as heparin and vitamin K antagonists and drugs that alter platelet function such as acetylsalicylic acid dipyridamole and GP IIb IIIa inhibitors may increase the risk of bleeding if administered prior to during or after TNKase therapy\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Carbamazepine, Rifampicin \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Carbamazepine, phenytoin \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Carbamazepine, carbamazepine \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Carbamazepine, rifampicin \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, ondansetron \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t carbamazepine, rifampicin \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t carbamazepine, ondansetron \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t Phenytoin Carbamazepine and Rifampicin In patients treated with potent inducers of CYP3A4 i.e. phenytoin carbamazepine and rifampicin the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t monoamine oxidase ( MAO ) inhibitors, alcohol \n",
      "Sentences: \n",
      "\tThe concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . \n",
      "\t The concomitant use of other CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines other opioids tricyclic antidepressants monoamine oxidase MAO inhibitors and alcohol may produce additive CNS depressant effects\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Imexon, dacarbazine \n",
      "Sentences: \n",
      "\tImexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells . \n",
      "\t Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Warfarin, citalopram \n",
      "Sentences: \n",
      "\tWarfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( OR = 1.73 [ 95 % CI , 1.25 - 2.38 ] ) , fluoxetine ( OR = 1.63 [ 95 % CI , 1.11 - 2.38 ] ) , paroxetine ( OR = 1.64 [ 95 % CI , 1.27 - 2.12 ] ) , amitriptyline ( OR = 1.47 [ 95 % CI , 1.02 - 2.11 ] ) . \n",
      "\t Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram OR = NUMBER NUMBER CI NUMBER NUMBER fluoxetine OR = NUMBER NUMBER CI NUMBER NUMBER paroxetine OR = NUMBER NUMBER CI NUMBER NUMBER amitriptyline OR = NUMBER NUMBER CI NUMBER NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t quinpirole, amphetamine \n",
      "Sentences: \n",
      "\tIn female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine . \n",
      "\t In female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Moxifloxacin, lomefloxacin \n",
      "Sentences: \n",
      "\tMoxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections . \n",
      "\t Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Lomefloxacin, sucralfate \n",
      "Sentences: \n",
      "\tMoxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi - minerals in neutral media . \n",
      "\t Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi minerals in neutral media\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t antiretroviral, Implanon \n",
      "Sentences: \n",
      "\tWe present an interesting case of an HIV - positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place . \n",
      "\t We present an interesting case of an HIV positive woman on antiretroviral therapy having tubal pregnancies on NUMBER separate occasions with Implanon in place\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t proton pump inhibitors, clopidogrel \n",
      "Sentences: \n",
      "\tContradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel -treated patients have been reported in literature . \n",
      "\t Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel -treated patients have been reported in literature\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t docetaxel, sunitinib \n",
      "Sentences: \n",
      "\tSunitinib as a single agent exhibits anti - proliferative effects in vitro in NSCLC cell lines with EGFR T790 M and K - ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration . \n",
      "\t Sunitinib as a single agent exhibits anti proliferative effects in vitro in NSCLC cell lines with EGFR T790 M and K ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t cyclooxygenase-2 inhibitors, chemotherapeutic agents \n",
      "Sentences: \n",
      "\tThis study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents . \n",
      "\t This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Infacol, levothyroxine \n",
      "Sentences: \n",
      "\tQuestioning revealed the child was taking Infacol drops before feeds while on levothyroxine . \n",
      "\t Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Ticlopidine, ketamine \n",
      "Sentences: \n",
      "\tTiclopidine treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC(0- ) ) of oral ketamine by 2.4-fold , whereas itraconazole treatment did not increase the exposure to S - ketamine . \n",
      "\t Ticlopidine treatment increased the mean area under the plasma concentration time curve extrapolated to infinity AUC(0- of oral ketamine by 2.4-fold whereas itraconazole treatment did not increase the exposure to S ketamine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t piperacillin, methylglyoxal \n",
      "Sentences: \n",
      "\tDistinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa . \n",
      "\t Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t dasatinib, paclitaxel \n",
      "Sentences: \n",
      "\tThe siRNA knockdown of p27(Kip1 ) decreased dasatinib - and paclitaxel -induced apoptosis compared with a negative control siRNA ( sub - G1 fraction , control siRNA vs. p27(Kip1 ) siRNA : 42.5 % vs. 20.1 % , difference = 22.4 % , 95 % CI = 20.1 % to 24.7 % , P = .017 ) . \n",
      "\t The siRNA knockdown of p27(Kip1 decreased dasatinib and paclitaxel -induced apoptosis compared with a negative control siRNA sub G1 fraction control siRNA vs. p27(Kip1 siRNA NUMBER vs. NUMBER difference = NUMBER NUMBER CI = NUMBER to NUMBER P = NUMBER\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, SSRI antidepressants \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer especially SSRI antidepressants such as paroxetine and fluoxetine\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, fluoxetine \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer especially SSRI antidepressants such as paroxetine and fluoxetine\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t doxycycline, MPTP \n",
      "Sentences: \n",
      "\tand/or antibiotic drug doxycycline ( 100 mg / kg , p. o. ) , as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( MPTP ) ( 4 x 20 mg / kg , i. p. ) \n",
      "\t and/or antibiotic drug doxycycline NUMBER mg kg p. o. as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine MPTP NUMBER x NUMBER mg kg i. p.\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Calcium, nonheme and heme iron iron \n",
      "Sentences: \n",
      "\tCalcium is the only known component in the diet that may affect absorption of both nonheme and heme iron iron . \n",
      "\t Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Calcium, heme iron \n",
      "Sentences: \n",
      "\tCalcium is the only known component in the diet that may affect absorption of both nonheme and heme iron iron . \n",
      "\t Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, nonheme ( as sulfate ) and heme ( as CRBC ) iron \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t In conclusion we demonstrated an isolated effect of calcium as chloride on absorption of NUMBER mg of iron provided as nonheme as sulfate and heme as CRBC iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, heme ( as CRBC ) iron \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t In conclusion we demonstrated an isolated effect of calcium as chloride on absorption of NUMBER mg of iron provided as nonheme as sulfate and heme as CRBC iron\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t GSLS, inactivated AI vaccines \n",
      "Sentences: \n",
      "\tIn experiment 2 , the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines , and an enhanced serum antibody response to AI vaccination was also observed . \n",
      "\t In experiment NUMBER the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines and an enhanced serum antibody response to AI vaccination was also observed\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print('We print the baseline first and then the punct digit version. Gold relation corresponds to baseline\\n\\n')\n",
    "curr_linenum = 0\n",
    "with open(original_sentences_path) as original_sentences, open(punct_digit_sentences_path) as punct_digit_sentences:\n",
    "    for x, y in zip(original_sentences, punct_digit_sentences):\n",
    "        needed_linenums = list(needed_linenum_and_relation.keys())\n",
    "        if curr_linenum in needed_linenums:\n",
    "            _, e1_b, e2_b, s_b = read_sentence_and_entities(x.strip())\n",
    "            _, e1_c, e2_c, s_c = read_sentence_and_entities(y.strip())\n",
    "            r_b, r_c = needed_linenum_and_relation[curr_linenum]\n",
    "            print('Predicted Relation: \\t {0}, {1} \\nEntities: \\t {2}, {3} \\nSentences: \\n\\t{4} \\n\\t {5}'.format(\n",
    "                    r_b, r_c, e1_b, e2_b, s_b, s_c))\n",
    "            print('\\n')\n",
    "        curr_linenum += 1"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
